by Stacey Johnson | Feb 23, 2024
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA)...
by Krystal Jacques | Jan 10, 2024
The Second World War (WWII) and post WWII saw an appetite for new technology and science. In particular, after WWII scientists were encouraged to conduct research for the sake of knowledge and to benefit society. However, there weren’t as many opportunities outside of...
by CCRM Australia | Sep 28, 2023
This blog post was written by Jimmy Yu (see LinkedIn page) with supervision by Dr. Chih Wei Teng. Countries that responded better during the COVID-19 pandemic showed good, coordinated efforts between different government agencies and departments. Known as the...
by Stacey Johnson | Sep 8, 2023
In 2019, CCRM launched a new blog to explain products, processes, terms, technologies, techniques and much more related to developing and manufacturing cell and gene therapy products. As a contract development and manufacturing organization (CDMO), CCRM wanted to...
by Stacey Johnson | Aug 22, 2023
It’s exciting news that there are close to 2,000 advanced therapies currently in clinical trials around the world. But is it good news? It’s exciting to see how far the cell and gene therapy (CGT) industry has come and how quickly the pipeline is growing. It’s...
by Michael May | Aug 22, 2023
The 10-year boom of the cell and gene therapy (CGT) industry has inevitably come to an end: public CGT valuations are way down, companies are settling into cash conservation mode, unrealistic salary demands are being replaced by layoffs, and the vultures circling with...
Comments